Lab-Grown mini tumors could unlock secrets of chemo resistance in breast cancer

NCT ID NCT07516626

Not yet recruiting Knowledge-focused Sponsor: Atlas University Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study will take tumor samples from 40 women with locally advanced breast cancer and grow them in the lab as 3D 'mini tumors' called organoids. Researchers will test how these organoids respond to chemotherapy and compare the results to how the patients actually responded. They will also test whether certain approved drugs can reverse chemotherapy resistance. The goal is to better understand why some cancers don't respond to treatment and to find ways to personalize therapy.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If successful, this could lead to a lab test that predicts which chemotherapy will work best for each patient, and identify existing drugs that can overcome resistance.
What could go wrong: This is an early observational study with only 40 participants, so results may not apply to all patients. The organoid models may not perfectly mimic real tumor behavior.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST CANCER LOCALLY ADVANCED BREAST CANCER (LABC)

Contacts and locations

Locations

Istanbul Atlas University Faculty of Medicine

Istanbul, Turkey (Türkiye)

More trials for these conditions

Other studies related to the condition(s) this trial covers.